There are 108 resources available
1619O - High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA67 - TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas
Presenter: Maud Toulmonde
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA68 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER
Presenter: Florence Duffaud
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA72 - Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19)
Presenter: Petros Grivas
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA73 - The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01
Presenter: Pia Kvistborg
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA74 - Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)
Presenter: Deborah Doroshow
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA75 - Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)
Presenter: Javier Baena Espinar
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
524O - Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours
Presenter: Lillian Siu
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
525O - A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
Presenter: Geoffrey Ku
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
526O - High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
Presenter: Benoit Rousseau
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast